intralesional triamcinolone to achieve control. Since then, she has initiated glycopyrrolate 1 mg 3 times per day and naltrexone 4.5 mg and achieved 30% clearance of HHD over the last 3 months. The patient is pleased because no lesions are exudative, eroded, or symptomatic.
Rituximab as Single Long-term Maintenance Therapy in Patients With Difficult-to-Treat Pemphigus
Pemphigus is a rare, chronic, relapsing, and potentially lifethreatening autoimmune bullous dermatosis. European guidelines recommend administration of systemic corticosteroids as a first-line therapy. 1 According to its previously published efficacy as a corticosteroid-sparing agent in refractory disease, rituximab, an anti-CD20 monoclonal antibody, is recommended as a second-or third-line therapy. [1] [2] [3] [4] A French randomized clinical trial demonstrated that rituximab is effective and well tolerated as a first-line therapy, enabling a marked decrease in cumulative dose and duration of co-administered corticosteroid. However, whether rituximab can be administered alone as a maintenance therapy for prevention of relapse to pemphigus remains unclear. We report our experience with rituximab used as a single, long-term maintenance therapy in 11 patients with severe, difficult-to-treat pemphigus.
Methods | This single-center, retrospective case-series study was conducted in our autoimmune bullous diseases reference center. We identified all consecutive patients from January 1 to December 31, 2014, with a confirmed diagnosis of pemphigus vulgaris or foliaceus treated with at least 1 cycle of rituximab for corticosteroid dependence, corticosteroid resistance, or adverse events. Among those, we included patients who received additional cycles of rituximab as a single maintenance therapy (ie, without any other treatment, such as a corticosteroid) and with a follow-up of 12 or more months after the first maintenance cycle. From patient medical records, we collected clinical data, rituximab administration regimens, follow-up information, and enzyme-linked immunosorbent assay results of serum autoantibody levels specific to desmoglein 1 and 3. The date of the last follow-up was August 31, 2017. This study was approved by the Reims University Hospital institutional review board, and all patients provided oral informed consent.
Results | Among 27 patients who received at least 1 cycle of rituximab, 11 patients (41%; 5 women; median [range] age, 42 years; all white individuals) received maintenance therapy. All were in complete remission and not taking any corticosteroid at the time of the first maintenance rituximab infusion ( Table 1) . The maintenance therapy regimen consisted of a single rituximab infusion (1 g) given every 6 months (but in some cases decreasing after 18 months to once yearly), with a median (range) duration of 33 (24-67) months, and the median (range) number of infusions was 6 (5-12) ( Table 1) . During maintenance therapy, all 11 patients remained in Abbreviations: Dsg, desmoglein; ND, not determined; Neg, negative (ie, <14 U/mL). a Serum levels determined using enzyme-linked immunosorbent assay kits (MBL International Corporation). In all patients, serum anti-Dsg 1 and 3 autoantibody levels were negative before the last rituximab infusion. , all 11 patients remained in complete remission, with 10 patients having discontinued rituximab maintenance therapy. Serum anti-desmoglein 1 and 3 antibody levels, which had been high before rituximab treatment, decreased markedly and remained below 14 U/mL during rituximab maintenance therapy ( Table 2) .
Discussion | The results of this case series indicated that rituximab can be used as single maintenance therapy, without a systemic corticosteroid, with good efficacy and tolerance in patients having severe pemphigus requiring long-term therapy for prevention of relapse. This study supplements a previous one showing the efficacy of rituximab alone in the treatment of relapse to pemphigus initially controlled with a combination of rituximab and corticosteroid. 6 We found that treatment with rituximab alone, even at a low dose, not only prevented relapse but also maintained complete remission with a better benefit to risk ratio than treatment with corticosteroids. The maintenance therapy was shown to be effective for preventing relapse despite shortcomings inherent in retrospective studies (eg, heterogeneity of patient pemphigus history and variable length of rituximab maintenance therapy), highlighting the feasibility of such an approach. A progressive decrease in serum anti-desmoglein autoantibody levels to less than 14 U/mL occurred in all cases along with clinical complete remission even after maintenance therapy cessation. Practical questions remain about the rituximab treatment regimen, including the optimal dose (500 mg or 1 g), frequency of administration (every 6 months or 1 year), and immunologic criteria enabling treatment withdrawal (negative direct immunofluorescence results or low serum autoantibody levels), and the cost-effectiveness of this maintenance therapy in patients with pemphigus. The criteria we used to discontinue rituximab maintenance therapy were persistent complete clinical remission and serum anti-desmoglein 1 and 3 autoantibody levels less than 14 U/mL for at least 1 year. Further prospective studies are warranted to identify patients for treatment with maintenance rituximab therapy and to optimize long-term management of difficult-to-treat pemphigus.
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Association of Facial Exercise With the Appearance of Aging
Physical manifestations of facial aging are now understood to include not only skin laxity and superficial photodamage but also deeper substructural volume loss of fat and muscle. 1 There has been recent interest in the lay community in facial exercises or facial "yoga" that can rejuvenate the aging face, presumably by inducing underlying muscle growth. [2] [3] [4] In this report, we describe what we believe to be the first clinical trial to assess facial exercise as a modality for improving skin appearance.
Methods | Healthy participants aged 40 to 65 years with photodamage, associated mild to moderate facial atrophy, and with an interest in facial exercises were included. Participants received formal instruction on 32 facial exercises. All participants attended 2 live 90-minute muscle-resistant facial exercise training sessions with a certified facial exercise instructor (G.S.). Neither participants nor those administering the interventions were blinded. After the initial training sessions with the instructor, participants performed daily 30-minute exercises for 8 weeks at home. During weeks 9 to 20, participants continued practicing exercises every other day (3-4 times per week). This study was approved by the Northwestern University Institutional Review Board and registered at ClinicalTrials .gov (NCT01689012) prior to participant enrollment. Written
